{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:20:53Z","timestamp":1787019653733,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,10,30]],"date-time":"2012-10-30T00:00:00Z","timestamp":1351555200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-2474-13-213","type":"journal-article","created":{"date-parts":[[2012,10,31]],"date-time":"2012-10-31T13:18:00Z","timestamp":1351689480000},"source":"Crossref","is-referenced-by-count":40,"title":["The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden"],"prefix":"10.1186","volume":"13","author":[{"given":"Daniel R","family":"Murphy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee J","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,30]]},"reference":[{"key":"1560_CR1","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/j.bone.2007.02.027","volume":"40","author":"F Borgstr\u00f6m","year":"2007","unstructured":"Borgstr\u00f6m F, Sobocki P, Str\u00f6m O, J\u00f6nsson B: The societal burden of osteoporosis in Sweden. Bone. 2007, 40: 1602-1609. 10.1016\/j.bone.2007.02.027.","journal-title":"Bone"},{"key":"1560_CR2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s001980070064","volume":"11","author":"JA Kanis","year":"2000","unstructured":"Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B: Long-term risk of osteoporotic fracture in Malm\u00f6. Osteoporos Int. 2000, 11: 669-674. 10.1007\/s001980070064.","journal-title":"Osteoporos Int"},{"key":"1560_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00198-008-0560-z","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster J-Y, Borgstrom F, Rizzoli R: European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008, 19: 399-428. 10.1007\/s00198-008-0560-z.","journal-title":"Osteoporos Int"},{"key":"1560_CR4","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH: Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001, 344: 1434-1441. 10.1056\/NEJM200105103441904.","journal-title":"N Engl J Med"},{"key":"1560_CR5","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","volume":"164","author":"R Lindsay","year":"2004","unstructured":"Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster J, Stepan JJ, Myers SL, Mitlak BH: Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004, 164: 2024-2030. 10.1001\/archinte.164.18.2024.","journal-title":"Arch Intern Med"},{"key":"1560_CR6","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1359\/JBMR.050501","volume":"20","author":"R Prince","year":"2005","unstructured":"Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH: Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res. 2005, 20: 1507-1513. 10.1359\/JBMR.050501.","journal-title":"J Bone Miner Res"},{"key":"1560_CR7","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1185\/030079905X49671","volume":"21","author":"HK Genant","year":"2005","unstructured":"Genant HK, Halse J, Briney WG, Xie L, Glass EV, Krege JH: The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis. Curr Med Res Opin. 2005, 21: 1027-1034. 10.1185\/030079905X49671.","journal-title":"Curr Med Res Opin"},{"key":"1560_CR8","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMoa071408","volume":"357","author":"KG Saag","year":"2007","unstructured":"Saag KG, Shane E, Boonen S, Mar\u00edn F, Donley DW, Taylor KA, Dalsky GP, Marcus R: Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007, 357: 2028-2039. 10.1056\/NEJMoa071408.","journal-title":"N Engl J Med"},{"key":"1560_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jbspin.2005.09.002","volume":"72","author":"P Orcel","year":"2005","unstructured":"Orcel P: Prevention and treatment of glucocorticoid-induced osteoporosis in 2005. Joint Bone Spine. 2005, 72: 461-465. 10.1016\/j.jbspin.2005.09.002.","journal-title":"Joint Bone Spine"},{"key":"1560_CR10","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","volume":"39","author":"TP van Staa","year":"2000","unstructured":"van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C: Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000, 39: 1383-1389. 10.1093\/rheumatology\/39.12.1383.","journal-title":"Rheumatology (Oxford)"},{"key":"1560_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0889-8529(02)00064-6","volume":"32","author":"KG Saag","year":"2003","unstructured":"Saag KG: Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am. 2003, 32: 135-157. 10.1016\/S0889-8529(02)00064-6. vii","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1560_CR12","unstructured":"TA161 Osteoporosis - secondary prevention including strontium ranelate: guidance. http:\/\/www.nice.org.uk\/ ,"},{"key":"1560_CR13","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta11070","volume":"11","author":"JA Kanis","year":"2007","unstructured":"Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M: Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess. 2007, 11: iii-iv. ix\u2013xi, 1\u2013231","journal-title":"Health Technol Assess"},{"key":"1560_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00198-005-1959-4","volume":"17","author":"J Lundkvist","year":"2006","unstructured":"Lundkvist J, Johnell O, Cooper C, Sykes D: Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women. Osteoporos Int. 2006, 17: 201-211. 10.1007\/s00198-005-1959-4.","journal-title":"Osteoporos Int"},{"key":"1560_CR15","unstructured":"TLV Historical Drug Prices. http:\/\/www.tlv.se\/beslut\/sok\/lakemedel\/ ,"},{"key":"1560_CR16","unstructured":"http:\/\/www.riksbanken.se ; average rate ending December 2011 [www.riksbanken.se]"},{"key":"1560_CR17","volume-title":"Regional Rates and Allowances for Southern Health Region 2011","author":"Sweden South Region Health Board Healthcare Region","year":"2010","unstructured":"Sweden South Region Health Board Healthcare Region: Regional Rates and Allowances for Southern Health Region 2011. 2010"},{"key":"1560_CR18","unstructured":"Sweden Life Tables for 2003\u20132007. http:\/\/www.scb.se\/ ,"},{"key":"1560_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00198-004-1688-0","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Borgstr\u00f6m F, Johnell O, Oden A, Sykes D, J\u00f6nsson B: Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int. 2005, 16: 15-25. 10.1007\/s00198-004-1688-0.","journal-title":"Osteoporos Int"},{"key":"1560_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00198-003-1490-4","volume":"15","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jonsson B: Mortality after osteoporotic fractures. Osteoporosis International. 2004, 15: 38-42. 10.1007\/s00198-003-1490-4.","journal-title":"Osteoporosis International"},{"key":"1560_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/eurpub\/9.3.211","volume":"9","author":"L Lundberg","year":"1999","unstructured":"Lundberg L, Johannesson M, Isacson DGL, Borgquist L: Health-state utilities in a general population in relation to age, gender and socioeconomic factors. Eur J Pub Health. 1999, 9: 211-217. 10.1093\/eurpub\/9.3.211.","journal-title":"Eur J Pub Health"},{"key":"1560_CR22","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s00223-009-9299-6","volume":"85","author":"BL Langdahl","year":"2009","unstructured":"Langdahl BL, Rajzbaum G, Jakob F, Karras D, Ljunggren O, Lems WF, Fahrleitner-Pammer A, Walsh JB, Barker C, Kutahov A, Marin F: Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int. 2009, 85: 484-493. 10.1007\/s00223-009-9299-6.","journal-title":"Calcif Tissue Int"},{"key":"1560_CR23","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s00198-006-0179-x","volume":"17","author":"D Weycker","year":"2006","unstructured":"Weycker D, Macarios D, Edelsberg J, Oster G: Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int. 2006, 17: 1645-1652. 10.1007\/s00198-006-0179-x.","journal-title":"Osteoporos Int"},{"key":"1560_CR24","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S8756-3282(03)00061-9","volume":"32","author":"JA Kanis","year":"2003","unstructured":"Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK: The components of excess mortality after hip fracture. Bone. 2003, 32: 468-73. 10.1016\/S8756-3282(03)00061-9.","journal-title":"Bone"},{"key":"1560_CR25","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00198-004-1762-7","volume":"16","author":"P Lips","year":"2005","unstructured":"Lips P, van Schoor NM: Quality of life in patients with osteoporosis. Osteoporos Int. 2005, 16: 447-455. 10.1007\/s00198-004-1762-7.","journal-title":"Osteoporos Int"},{"key":"1560_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11926-007-0022-1","volume":"9","author":"JT Schousboe","year":"2007","unstructured":"Schousboe JT: Cost-effectiveness modeling research of pharmacologic therapy to prevent osteoporosis-related fractures. Curr Rheumatol Rep. 2007, 9: 50-56. 10.1007\/s11926-007-0022-1.","journal-title":"Curr Rheumatol Rep"},{"key":"1560_CR27","unstructured":"Statistics Sweden: CPI Historical numbers, 1830. http:\/\/www.scb.se\/Pages\/TableAndChart____33896.aspx ,"},{"key":"1560_CR28","doi-asserted-by":"publisher","first-page":"734","DOI":"10.7326\/0003-4819-142-9-200505030-00008","volume":"142","author":"JT Schousboe","year":"2005","unstructured":"Schousboe JT, Nyman JA, Kane RL, Ensrud KE: Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med. 2005, 142: 734-741.","journal-title":"Ann Intern Med"},{"key":"1560_CR29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3111\/13696998.2010.499072","volume":"13","author":"F Borgstr\u00f6m","year":"2010","unstructured":"Borgstr\u00f6m F, Str\u00f6m O, Marin F, Kutahov A, Ljunggren O: Cost effectiveness of teriparatide and PTH(1\u201384) in the treatment of postmenopausal osteoporosis. J Med Econ. 2010, 13: 381-392. 10.3111\/13696998.2010.499072.","journal-title":"J Med Econ"},{"key":"1560_CR30","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00198-009-0844-y","volume":"20","author":"T Peasgood","year":"2009","unstructured":"Peasgood T, Herrmann K, Kanis JA, Brazier JE: An updated systematic review of Health State Utility Values for osteoporosis related conditions. Osteoporos Int. 2009, 20: 853-868. 10.1007\/s00198-009-0844-y.","journal-title":"Osteoporos Int"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-13-213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2474-13-213\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-13-213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,13]],"date-time":"2016-07-13T00:42:25Z","timestamp":1468370545000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/1471-2474-13-213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,30]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["1560"],"URL":"https:\/\/doi.org\/10.1186\/1471-2474-13-213","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,30]]},"article-number":"213"}}